Alnylam gets FDA nod for first-ever RNAi drug
The U.S. FDA has approved Alnylam Pharmaceuticals ’ Onpattro, making it the first medicine specifically cleared to treat a rare and deadly disease called hereditary transthyretin amyloidosis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 13, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Onpattro (patisiran) Targeted RNA-based Therapy for Polyneuropathy Caused by hATTR
August 10, 2018 -- The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 10, 2018 Category: Drugs & Pharmacology Source Type: news

Patisiran Wins Two Firsts With FDA Approval
(MedPage Today) -- RNAi drug OK'd to treat polyneuropathy from hereditary transthyretin amyloidosis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 10, 2018 Category: Primary Care Source Type: news

Cambridge biotech Alnylam wins FDA approval for first drug
The FDA has approved Alnylam Pharmaceuticals Inc.'s first drug, a novel rare disease treatment that analysts believe could eventually top $1 billion in annual sales, marking a major milestone for one of the state's fastest-growing biotechs. The FDA said Friday it had approved Cambridge-based Alnylam's (Nasdaq: ALNY) drug patisiran, which targets a rare and often fatal genetic disease called hereditary ATTR amyloidosis, or hATTR amyloidosis. The disorder, which affects around 50,000 people worldwide,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 10, 2018 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
FDA approves new drug for treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR). This is the first FDA-approved treatment for this rare, debilitating and often fatal genetic disease and the first FDA approval of a new class of drugs called small interfering ribonucleic acid (siRNA) treatment. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 10, 2018 Category: American Health Source Type: news

First RNAi Therapy Approved by FDA
Alnylam's patisiran interferes with the production of a mutated protein present in people with hereditary transthyretin amyloidosis. (Source: The Scientist)
Source: The Scientist - August 10, 2018 Category: Science Tags: News & Opinion Source Type: news

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, debilitating and often fatal genetic disease characterized by the buildup of abnormal amyloid protein in peripheral nerves, the heart and other organs. (Source: World Pharma News)
Source: World Pharma News - August 10, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

First Case of Pulmonary Amyloidosis in a Dental Technician First Case of Pulmonary Amyloidosis in a Dental Technician
A dental technician developed multiple granulomas with amyloid deposition in the lungs after occupational exposure to silica. What can we learn from this rare case?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

New Agents Show Promise for Severe and Fatal Genetic Disease New Agents Show Promise for Severe and Fatal Genetic Disease
Hereditary transthyretin amyloidosis is caused by mutation in the TTR gene. Two promising new agents may slow the progression and improve the symptoms of this progressive and fatal disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Patisiran, Inotersen Aid Hereditary Transthyretin Amyloidosis
THURSDAY, July 5, 2018 -- For patients with hereditary transthyretin amyloidosis with polyneuropathy, an investigational RNA interference therapeutic agent (patisiran) and a 2'-O-methoxyethyl-modified antisense oligonucleotide (inotersen), which... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 5, 2018 Category: Pharmaceuticals Source Type: news

Oligonucleotide Drugs Show Promise in Transthyretin Amyloidosis (CME/CE)
(MedPage Today) -- Patisiran, inotersen show peripheral neuropathy progression can be slowed (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - July 5, 2018 Category: Neurology Source Type: news

New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life CARLSBAD, Calif., and CAMBRIDGE, Mass., July 5, 2018 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS... Biopharmaceuticals, Neurology Ionis Pharmaceuticals, Akcea Therapeutics, TEGSEDI, inotersen, hATTR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 5, 2018 Category: Pharmaceuticals Source Type: news

Alliance Medical Group acquires Piramal Imaging
The Alliance Medical Group has reached an agreement to acquire Piramal Imaging,...Read more on AuntMinnie.comRelated Reading: Are amyloid PET scans ready for the clinical setting? PET with novel tracers foretells early Alzheimer's risk Piramal partner gets Canadian approval for NeuraCeq JNM: Florbetaben-PET detects cardiac amyloidosis Piramal Imaging inks Taiwan deal (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 2, 2018 Category: Radiology Source Type: news

Are amyloid PET scans ready for the clinical setting?
The use of PET scans to confirm the presence of dementia-inducing amyloid plaque...Read more on AuntMinnie.comRelated Reading: PET links amyloid, vascular factors to cognitive decline PET with novel tracers foretells early Alzheimer's risk PiB-PET study strengthens link between amyloid, dementia High amyloid levels on PET may indicate early Alzheimer's JNM: Florbetaben-PET detects cardiac amyloidosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2018 Category: Radiology Source Type: news

CHMP Recommends Approval for Inotersen in hATTR CHMP Recommends Approval for Inotersen in hATTR
Inotersen has won recommendation of the EMA's Committee for Medicinal Products for Human Use for treatment of hereditary transthyretin amyloidosis.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Lifetime Risks Temper Biomarker Tests for Alzheimer Dz Dementia
Those younger than 85 years with MCI, amyloidosis, neurodegeneration have risk>50 percent (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - June 7, 2018 Category: Psychiatry Tags: Neurology, Pathology, Psychiatry, Journal, Source Type: news

AD Link Between APOE, Tau Stronger in Women
(MedPage Today) -- But no association seen with amyloidosis or tangles (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 8, 2018 Category: Neurology Source Type: news

APOLLO: Patisiran Reduces Polyneuropathy in hATTR Amyloidosis APOLLO: Patisiran Reduces Polyneuropathy in hATTR Amyloidosis
Randomized data from the APOLLO phase 3 study show significant improvement in polyneuropathy with treatment,'the first time in the amyloid story,'researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 26, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Woodford-backed biotech Prothena plunges as key drug fails
LONDON (Reuters) - Shares in Prothena, a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial. (Source: Reuters: Health)
Source: Reuters: Health - April 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Eidos Therapeutics completes $64M Series B financing
Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials SAN FRANCISCO, April 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eidos Thera... Biopharmaceuticals, Venture Capital Eidos Therapeutics, transthyretin amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2018 Category: Pharmaceuticals Source Type: news

Case: Breast Amyloidosis Detected With 3D Mammography Case: Breast Amyloidosis Detected With 3D Mammography
Review the imaging characteristics of breast amyloidosis in this unusual case. How should definitive diagnosis be made?Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2018 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 1, 2018 Category: Drugs & Pharmacology Source Type: news

Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 12, 2017 Category: Drugs & Pharmacology Source Type: news

U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 20, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 20, 2017 Category: Drugs & Pharmacology Source Type: news

Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 16, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 16, 2017 Category: Drugs & Pharmacology Source Type: news

Alnylam shares hit all-time high as rare disease drug continues to impress
Alnylam Pharmaceuticals added more than $1.5 billion to its market cap on Thursday after unveiling new data from a closely watched trial of its lead rare disease drug, which appeared to outperform a competitor ’s drug targeting the same disorder. Alnylam (Nasdaq: ALNY) reported new details from a Phase 3 trial of patisiran, a potential treatment for a disease called amyloidosis ­that affects around 10,000 people. The company previously said in September that the study had met all of its goals,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Inotersen Shows Efficacy in Hereditary ATTR Inotersen Shows Efficacy in Hereditary ATTR
Improvements in neurologic and quality-of-life endpoints were seen in patients with hereditary transthyretin amyloidosis with polyneuropathy by using the investigational drug inotersen; side effects were called'monitorable. 'Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 20, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

BU researcher receives NIH award to better understand wild-type transthyretin amyloidosis
(Boston University School of Medicine) Lawreen H. Connors, PhD, associate professor of pathology and laboratory medicine and biochemistry at Boston University School of Medicine (BUSM), is the recipient of a National Institutes of Health (NIH) High Priority, Short-Term Project Award, for her research 'molecular mechanism of senile cardiac amyloidosis.' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2017 Category: International Medicine & Public Health Source Type: news

Experimental Alnylam drug hits mark in late-stage study, lifting shares
Alnylam Pharmaceuticals said Wednesday that its lead experimental drug for a rare disease had passed a late-stage trial, adding more than $1.5 billion to the Cambridge company ’s market cap in pre-market trading and potentially paving the way for a first-of-its-kind treatment to hit the market. Alnylam (Nasdaq: ALNY) said that the Phase 3 study of patisiran, which targets a disease called amyloidosis ­that affects around 10,000 people, had met all of its goals. Import antly, the company and its… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 20, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Distal Bicep Tendon Rip Tied to Transthyretin Amyloidosis
Findings in patients with heart failure with preserved ejection fraction (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 13, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Orthopedics, Pathology, Pulmonology, Journal, Source Type: news

Faster diagnosis of inherited and lethal nerve disease could advance search for new treatments
(Johns Hopkins Medicine) Johns Hopkins physicians report success in a small study of a modified skin biopsy that hastens the earlier diagnosis of an inherited and progressively fatal nerve disease and seems to offer a clearer view of the disorder's severity and progression. With a quicker and less invasive way to visualize the hallmark protein clumps of the rare but lethal disease -- familial transthyretin amyloidosis -- the researchers say they hope to more rapidly advance clinical trials of treatments that may slow the disease and extend patients' lives. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2017 Category: International Medicine & Public Health Source Type: news

X-Rays Of The Earliest Stage Of Alzheimer's Offer Critical Clue About How It Starts
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com. Sarah DiGiulio is The Huffington Post’s sleep reporter. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - March 27, 2017 Category: Consumer Health News Source Type: news

X-Rays Of The Earliest Stage Of Alzheimer's Offer Critical Clue About How It Starts
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com. Sarah DiGiulio is The Huffington Post’s sleep reporter. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - March 27, 2017 Category: Science Source Type: news

Discovery's Edge: Cell research on amyloidosis
At Mayo Clinic, Marina Ramirez-Alvarado, Ph.D., studies one type of protein abnormality associated with a complex and incurable disease called light chain amyloidosis. This type of amyloidosis is the most common and can affect the heart, kidneys, skin, nerves, and liver.?Dr. Ramirez-Alvarado and her team just published a paper on their most recent findings in [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 21, 2017 Category: Databases & Libraries Source Type: news

New Options for Treating AL Amyloidosis
New treatment options are now available for light-chain amyloidosis, with additional ones on the way, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies. (Source: CancerNetwork)
Source: CancerNetwork - February 23, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Hematologic Malignancies Conferences/ICHM 2017 News Source Type: news

Circulating RBP4 IDs HF Caused by Transthyretin Amyloidosis (CME/CE)
(MedPage Today) --'Simple blood test'for underrecognized cause of heart failure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 8, 2017 Category: Cardiology Source Type: news

Engineering team finds compound may halt molecular cause of often-fatal condition
A team of engineers say a compound found in green tea could have lifesaving potential for patients with multiple myeloma and amyloidosis, who face often-fatal medical complications associated with bone-marrow disorders. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 6, 2017 Category: Science Source Type: news

The power of tea
(Washington University in St. Louis) A team of engineers at Washington University in St. Louis and their German collaborators say a compound found in green tea could have lifesaving potential for patients with multiple myeloma and amyloidosis, who face often-fatal medical complications associated with bone-marrow disorders. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 6, 2017 Category: Biology Source Type: news

Amyloidosis Treatments Miss the Heart of the Problem
(MedPage Today) -- Only modest improvement in end organ function (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 7, 2016 Category: Urology & Nephrology Source Type: news

With promising results from emerging therapies, research yields hope for amyloidosis
Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies. Immunoglobulin light-chain amyloidosis (AL) is a rare, life-threatening disease that occurs when toxic proteins build up in organs, which alters their normal function. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 1, 2016 Category: Science Source Type: news

With promising results from emerging therapies, Penn research yields hope for amyloidosis
(University of Pennsylvania School of Medicine) Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies involving researchers in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2016 Category: Cancer & Oncology Source Type: news

[Research Article] De novo design of a biologically active amyloid
Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. We designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. We found that amyloid toxicity is observed only in cells that both express VEGFR2 and a...
Source: ScienceNOW - November 10, 2016 Category: Science Authors: Rodrigo Gallardo Source Type: news

JNM: Florbetaben-PET detects cardiac amyloidosis
Australian researchers have shown the proficiency of PET with the radiotracer...Read more on AuntMinnie.comRelated Reading: Piramal Imaging inks Taiwan deal Scintigraphy detects amyloid-related heart condition Florbetaben-PET finds more beta-amyloid plaques Florbetapir shows promise in detecting cardiac amyloid Study shows PiB-PET detects amyloid plaque in heart (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 4, 2016 Category: Radiology Source Type: news

PET imaging visualizes hard-to-diagnose cardiac amyloidosis
(Society of Nuclear Medicine) Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal deposits of proteins in the heart), which is notoriously difficult to diagnose, can be visualized noninvasively with positron emission tomography (PET) using the radiotracer fluorine-18 (F-18)-florbetaben. The study is published in the November issue of 'The Journal of Nuclear Medicine.' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 1, 2016 Category: Global & Universal Source Type: news

Planar Cardiac Imaging Spots Transthyretin Cardiac Amyloidosis Planar Cardiac Imaging Spots Transthyretin Cardiac Amyloidosis
Technetium 99mpyrophosphate (Tc99mPYP) cardiac imaging effectively and noninvasively identifies transthyretin cardiac amyloidosis (ATTR-CA), according to findings from an observational study.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 2, 2016 Category: Radiology Tags: Radiology News Source Type: news

DHA May Slow Cognitive Decline
There is a wealth of evidence that omega-3 fats such as DHA, found in salmon and other fish, play a role in both brain and heart health. In fact, infant formulas are supplemented with a type of DHA because it is critical to newborns' brain development. Now, a new study published in JAMA Neurology has shown an association between low levels of DHA and cerebral amyloidosis, a precursor of the beta-amyloid plaques common in the brains of people with Alzheimer's disease. The researchers took blood samples and conducted Amyvid PET scans of the brains of 61 seniors who did not show signs of cognitive impairment. (These scans, ...
Source: Healthy Living - The Huffington Post - August 17, 2016 Category: Consumer Health News Source Type: news

Potential drug candidates could intervene in deadly diseases
Scientists have identified drug candidates that can boost a cell's ability to catch the 'typos' in protein production that can cause a deadly disease called amyloidosis, revealing a new approach to intervene in human disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 20, 2016 Category: Science Source Type: news

TSRI team finds potential drug candidates that could intervene in deadly diseases
(Scripps Research Institute) In a new study, scientists at The Scripps Research Institute have identified drug candidates that can boost a cell's ability to catch the 'typos' in protein production that can cause a deadly disease called amyloidosis, revealing a new approach to intervene in human disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2016 Category: Global & Universal Source Type: news

Bortezomib-Based Chemo Ups AL Cardiac Amyloidosis SurvivalBortezomib-Based Chemo Ups AL Cardiac Amyloidosis Survival
Heart failure due to light-chain amyloidosis is "one of the most devastating diagnoses a cardiologist may give a patient," one expert observes. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Diabetes drugs may be useful for Alzheimer's, mice research finds
Conclusion Both Alzheimer's disease and diabetes seem to have become more common in recent years, causing illness and putting strain on the health service. News that the two illnesses may have a common cause raises hopes that drugs which help with one disease may also be of use in treating another. Trials of a diabetes drug on people with Alzheimer's disease are reported to be underway, although no results have been published yet. This study, suggesting a mechanism which may be involved in the early stages of both diseases, may increase the likelihood that common treatments will be useful. The study's main limitation is th...
Source: NHS News Feed - June 22, 2016 Category: Consumer Health News Tags: Neurology Mental health Diabetes Source Type: news